A multicenter, open-label study to determine the safety and efficacy of single-agent CC-5013 [lenalidomide] in subjects with relapsed or refractory multiple myeloma.

Trial Profile

A multicenter, open-label study to determine the safety and efficacy of single-agent CC-5013 [lenalidomide] in subjects with relapsed or refractory multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2009 Actual end date changed from Dec 2005 to Mar 2007 as reported by ClinicalTrials.gov.
    • 08 Jun 2009 An analysis of this trial is to be presented at the 14th Congress of the European Hematology Association (EHA), according to a Celgene media release.
    • 06 Jun 2008 Status changed to completed as reported in an abstract presented at ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top